The Molecular Mechanism of Arsenic Trioxide-Induced Apoptosis and Oncosis in Leukemia/Lymphoma Cell Lines

Jiebin Zhu, Hirokazu Okumura, Shigeki Ohtake, Shinobu Nakamura, Shinji Nakao

Acta Haematologica · 2003 · 35 citations · 29 references

Concepts

Abstract

The mechanisms of As<sub>2</sub>O<sub>3</sub>-induced apoptosis are very complex. In the present study, we investigated the molecular mechanism of As<sub>2</sub>O<sub>3</sub> in vitro at low concentration (0.25–2.0 µ<i>M</i>) on three human leukemia/lymphoma cell lines: HL-60, RL and K562. As<sub>2</sub>O<sub>3</sub> inhibited the growth of these cell lines significantly. During As<sub>2</sub>O<sub>3</sub> treatment, two forms of cell death, apoptosis in HL-60 and RL and oncosis in K562, were found by morphological study. In HL-60 and RL, cell cycle analysis showed, at a distinct SubG1 region, that CD95 and CD95 ligand (CD95L) expression was upregulated, caspase 8 and caspase 3 were activated, and Bcl-2 protein expression was downregulated. On the other hand, in K562, the cell cycle was arrested at the G2+M phase, CD95/CD95L expression was upregulated, caspase 8 and caspase 3 were activated, but Bcl-2 expression was not changed as compared with untreated cells. These findings suggest that the CD95/CD95L pathway is involved in cell killing by As<sub>2</sub>O<sub>3</sub>. Using anti-CD95 IgG monoclonal antibody (anti-CD95 MoAb) or specific caspase inhibitor ZVAD-fmk to block the CD95 pathway, the cell death induced by As<sub>2</sub>O<sub>3</sub> was partially blocked in each cell line. These results suggest that As<sub>2</sub>O<sub>3</sub> inhibits the growth of these leukemia/lymphoma cell lines by inducing apoptosis or oncosis that is partially mediated by the CD95/CD95L pathway.

References

29